https://pittplusme.org/study/1535
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Have you been diagnosed with moderate-to-severe plaque psoriasis for at least 6 months? If so, you may be eligible to participate in a study of an investigational drug called risankizumab in subjects with plaque psoriasis. Involves 5 visits over 60 weeks. Compensation is provided.
IRB: 33998/16
- A Multicenter, Single-Arm, Open Label, Assessor-Blinded Study to Assess the Usability of the Risankizumab Autoinjector Combination Product in Adult Patients with Moderate to Severe Plaque Psoriasis
AGE:
18 and up
DURATION:
Up to 60 weeks
VISITS:
5 in-person visits & a phone call
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
$50 per visit
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.